Hostname: page-component-7b7567c8c-48dgx Total loading time: 0 Render date: 2026-11-18T07:26:31.972Z Has data issue: false hasContentIssue false

Kaleidoscope

Published online by Cambridge University Press:  02 January 2018

Rights & Permissions [Opens in a new window]

Extract

Special K’ has had various connotations over the years, and with respect to depressive illness ketamine has most recently been mooted as a potential antidepressant. It is intriguing because of its almost immediate effects, and a pharmacology that has little connection with the predominant monoamine hypothesis. How does its blockade ofglutamatergic NMDA receptors alleviate depressed mood? New data1suggest that a critical step is that this stabilises an adaptor protein,14-3-3η, which decouples GABAB receptor signalling and influencesthe activity of the intracellular protein mTOR. The upshot is a change insynaptic structure that produces a therapeutic effect; the ratherinnocuously named 14-3-3η protein seems to be the essential link forfast-acting antidepressants. Formidable problems exist with using ketamineas a therapeutic option, including a very quick decay in effectiveness, aswell as concerns about the intravenous administration of a compound that isan anaesthetic, a commonly misused recreational drug, and a pro-psychotic.However, an improved understanding of its mechanisms of action is essentialin enhancing our knowledge of the neuropathology of depression, offering thepotential for development of novel compounds circumventing some of theselimiting factors.

Information

Type
Columns
Copyright
Copyright © Royal College of Psychiatrists, 2015 

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.